Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | colorectal carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | colorectal carcinoma | predicted - sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 17% (4/24) of pretreated patients with CD274 (PD-L1)-positive colorectal carcinoma (PMID: 29284010; NCT02054806). | 29284010 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29284010) | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. | Full reference... |